MATTHEW FRANZ: Open Payments
NPI 1669055166 · FLINT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$941 in 33 payments from 15 companies in 2025. Trend: 2023 $281 · 2024 $441 · 2025 $941
Food & beverage: $902Education: $39
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $219 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $147 |
| GENZYME CORPORATION | 1 | $125 |
| EVOKE PHARMA, INC. | 1 | $125 |
| Lilly USA, LLC | 3 | $80 |
| Regeneron Healthcare Solutions, Inc. | 2 | $60 |
| QOL Medical, LLC | 2 | $46 |
| Celltrion USA Inc. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $21 |
Products named: TREMFYA, DUPIXENT, GIMOTI, EOHILIA, OMVOH, ENTYVIO, Sucraid, VEGZELMA.
Industry payments across MI — which companies pay providers there.
